The SEER Inquiry System (SINQ) is a searchable collection of questions that cancer registrars have had while coding cancer cases. These are questions submitted by designated registrars in SEER registries. The questions are answered by expert staff and go through a rigorous review process by NCI SEER staff and designated SEER registry staff before being added to SINQ.

Click Search to look for specific questions in SINQ or to select questions for a Report.

If you cannot find an answer to your question, refer to the Ask a SEER Registrar page.

Recent Questions
<< First    < Prev 10    11 to 20 of 2067    Next 10 >    Last >>
Add to Report ID Question Status Last Updated

Solid Tumor Rules (2018)/Histology--Lung:  What is the correct histology of a lung mass with a CT-directed fine needle aspirate–positive for malignancy, favor squamous cell carcinoma. See Discussion.

Final Dec 20 2018

Solid Tumor Rules (2018)/Histology--Lung: If the pathology states non-small cell carcinoma of the lung (NSCLC), consistent with squamous cell carcinoma, is the code non-small cell carcinoma according to the Solid Tumor Rules? The Medical Oncologist states that the tumor is a squamous cell carcinoma. In these instances would you code the squamous cell carcinoma since you have a definite physician statement?

Final Dec 20 2018

First Course Treatment--Other Therapy: Please explain how to code this new therapy, peptide receptor radionuclide therapy (PRRT) for rare neuroendocrine tumors.  See Discussion.

Final Dec 03 2018

2018 Solid Tumor Rules/Histology--Lung:  What is the appropriate histology code for the case below in the Discussion section? Is there a difference between adenocarcinoma in situ (bronchioloalveolar carcinoma), non-mucinous type (8252/2) and adenocarcinoma in-situ, mucinous? See Discussion.

Final Nov 29 2018

Reportability--Ambiguous terminology: Are the following terms reportable: almost certainly and until proven otherwise? See Discussion.

Final Nov 26 2018

Histology/Grade--Small intestine:  For a 2017 diagnosis, is the grade/differentiation field coded 1 or 9 when the diagnosis is well-differentiated neuroendocrine tumor (NET) (carcinoid)? It seems as though the term well-differentiated defines type of neuroendocrine tumor so they can diagnosis the carcinoid.  See Discussion.

Final Nov 15 2018

Solid Tumor Rules 2018/Histology--Brain and CNS: What code should be used for high grade neuroepithelial tumor with BCOR Alteration?  See Discussion

Final Nov 06 2018

Histology--Kidney:  What is the histology code for renal cell clear cell of the kidney with subsequent epithelioid angiomyolipoma PEComa of the liver stated to be metastatic? Case originaly diagnosed in 2016. See discussion.

Final Nov 01 2018

Reportability/Primary Site--Skin: Is vulvar intraepithelial neoplasia III (VIN III) or associated invasive squamous cell carcinoma reportable when stated to be of the perineum or perineal body or skin of perineum? See Discussion.

Final Oct 31 2018

Solid Tumor Rules (2018)/Histology: Please provide further explanation for prioritizing biomarkers in the histology coding rules.  See Discussion. 

Final Oct 25 2018
< Prev 10    Next 10 >